Roche Holding Ltd

RO

Equity

ISIN CH0012032113 / Valor 1203211

SIX Swiss Exchange (2024-09-18)

CHF 286.80+0.42%

Roche Holding Ltd
UMushroom community rating:

4.50 2 votes No rating yet

NegativeNeutralPositive

About company

Roche Holding Ltd is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The company operates through autonomous research and development centers and maintains alliances with over 250 external partners, which enhances its innovative capabilities and agility in responding to changes in the healthcare sector. Roche's commitment to diversity and inclusion in its leadership and workforce fosters a culture of integrity, courage, and passion, driving forward its mission to deliver significant medical benefits to patients. With a vast geographical reach, Roche is well-positioned to attract top talent and quickly deliver its solutions worldwide, aiming to provide value not only to patients and healthcare providers but also to its employees and investors by offering a sustainable and positive contribution to society.

Summarized from source with an LLMView SourceSector: Healthcare

Group Sales and Margin Trends

In the first quarter of 2023, Roche Holding Ltd reported group sales of CHF 58.7 billion, reflecting a slight decrease of 1% compared to the previous year. Despite the challenges posed by the COVID-19 pandemic, the company managed to maintain a strong performance across its various business segments.

Core Operating Profit

Roche Holding Ltd's core operating profit for Q1 2023 stood at CHF 58.7 billion, marking a 1% decline from the same period in the previous year. This slight decrease was attributed to the ongoing impact of the pandemic on certain business operations and market conditions.

Core Earnings per Share

For the first quarter of 2023, Roche Holding Ltd reported core earnings per share of CHF 18.57, which represents a 6% increase compared to the previous year. This growth in earnings per share highlights the company's ability to generate value for its shareholders despite external challenges.

Operating Free Cash Flow

Roche Holding Ltd achieved an operating free cash flow of CHF 15.8 billion in Q1 2023, reflecting a 4% increase from the previous year. This positive cash flow performance underscores the company's strong financial health and operational efficiency.

Dividend Increases

In line with its commitment to returning value to shareholders, Roche Holding Ltd announced a dividend increase for the 37th consecutive year in Q1 2023. The gross dividend for Roche was reported to have a 2% compound annual growth rate (CAGR), demonstrating the company's consistent financial performance and shareholder focus.

Summarized from source with an LLMView Source

Key figures

3.09%1Y

-25.0%3Y

2.72%5Y

Performance

21.8%1Y

21.1%3Y

21.5%5Y

Volatility